OTCPK:GTHP

Stock Analysis Report

Executive Summary

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices.

Snowflake

Fundamentals

Weak fundamentals or lack of information.


Similar Companies

Share Price & News

How has Guided Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.6%

GTHP

3.2%

US Medical Equipment

3.4%

US Market


1 Year Return

-86.0%

GTHP

10.0%

US Medical Equipment

5.4%

US Market

Return vs Industry: GTHP underperformed the US Medical Equipment industry which returned 10% over the past year.

Return vs Market: GTHP underperformed the US Market which returned 5.4% over the past year.


Shareholder returns

GTHPIndustryMarket
7 Day5.6%3.2%3.4%
30 Day-1.5%-1.8%-1.0%
90 Day-13.4%-0.4%-0.4%
1 Year-86.0%-86.0%10.9%10.0%7.7%5.4%
3 Year-100.0%-100.0%69.9%64.8%46.2%36.8%
5 Year-100.0%-100.0%128.2%102.9%65.6%47.5%

Price Volatility Vs. Market

How volatile is Guided Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Guided Therapeutics undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Guided Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Guided Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of GTHP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Guided Therapeutics regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is Guided Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.8%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Guided Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of GTHP’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Guided Therapeutics's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Guided Therapeutics performed over the past 5 years?

23.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GTHP is unprofitable, but has reduced losses over the past 5 years at a rate of 23.4% per year.

Accelerating Growth: Unable to compare GTHP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GTHP is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: GTHP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: GTHP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: GTHP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Guided Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: GTHP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: GTHP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: GTHP has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: GTHP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: GTHP has a high level of physical assets or inventory.

Debt Coverage by Assets: GTHP has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: GTHP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: GTHP has less than a year of cash runway if free cash flow continues to grow at historical rates of 45% each year.


Next Steps

Dividend

What is Guided Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate GTHP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate GTHP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if GTHP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if GTHP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of GTHP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Guided Therapeutics's salary, the management and board of directors tenure and is there insider trading?

5.8yrs

Average management tenure


CEO

Gene Cartwright (65yo)

5.8yrs

Tenure

0

Mr. Gene S. Cartwright, Ph.D. has been the Chief Executive Officer at Guided Therapeutics, Inc since January 2014 and its President and Acting Chief Financial Officer since January 2014. Mr. Cartwright ser ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Gene's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Gene's compensation has been consistent with company performance over the past year.


Management Age and Tenure

5.8yrs

Average Tenure

64yo

Average Age

Experienced Management: GTHP's management team is seasoned and experienced (5.8 years average tenure).


Board Age and Tenure

5.9yrs

Average Tenure

64.5yo

Average Age

Experienced Board: GTHP's board of directors are considered experienced (5.9 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Rick Fowler (63yo)

    Senior Vice President of Engineering and Secretary

    • Tenure: 17.2yrs
    • Compensation: US$62.02k
  • Mark Faupel (64yo)

    COO & Director

    • Tenure: 2.8yrs
  • Gene Cartwright (65yo)

    CEO, President

    • Tenure: 5.8yrs

Board Members

  • Mark Faupel (64yo)

    COO & Director

    • Tenure: 2.8yrs
  • Mike James (61yo)

    Chairman of the Board

    • Tenure: 6yrs
  • John Imhoff (70yo)

    Director

    • Tenure: 13.5yrs
  • Gene Cartwright (65yo)

    CEO, President

    • Tenure: 5.8yrs

Company Information

Guided Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Guided Therapeutics, Inc.
  • Ticker: GTHP
  • Exchange: OTCPK
  • Founded: 1992
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$629.913k
  • Shares outstanding: 3.32m
  • Website: https://www.guidedinc.com

Number of Employees


Location

  • Guided Therapeutics, Inc.
  • 5835 Peachtree Corners East
  • Suite D
  • Norcross
  • Georgia
  • 30092
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GTHPOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJul 1997

Biography

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. The company focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/16 00:13
End of Day Share Price2019/10/15 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.